Cargando…

Network analysis indicating the pharmacological mechanism of Yunpi-Qufeng-Chushi-prescription in prophylactic treatment of rheumatoid arthritis

BACKGROUND: Rheumatoid arthritis (RA), is an autoimmune inflammatory disease with increasing global morbidity and high disability. Early treatment is an effective intervention to slow down joint deformation. However, as for early RA and pre-RA patients, it sometimes takes a long time to make a defin...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lin, Zhou, Donghai, Liu, Qiuping, Li, Dianming, Wang, Qiao, Shi, Xiaowei, Wen, Chengping, Huang, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122573/
https://www.ncbi.nlm.nih.gov/pubmed/33992108
http://dx.doi.org/10.1186/s12906-021-03311-4
_version_ 1783692654413873152
author Li, Lin
Zhou, Donghai
Liu, Qiuping
Li, Dianming
Wang, Qiao
Shi, Xiaowei
Wen, Chengping
Huang, Lin
author_facet Li, Lin
Zhou, Donghai
Liu, Qiuping
Li, Dianming
Wang, Qiao
Shi, Xiaowei
Wen, Chengping
Huang, Lin
author_sort Li, Lin
collection PubMed
description BACKGROUND: Rheumatoid arthritis (RA), is an autoimmune inflammatory disease with increasing global morbidity and high disability. Early treatment is an effective intervention to slow down joint deformation. However, as for early RA and pre-RA patients, it sometimes takes a long time to make a definite diagnosis and few guidelines have made suggestion for these suspected or early phrase individuals. Yunpi-Qufeng-Chushi-Prescription (YQCP) is an optimization of the traditional formula, Cangzhu Fangfeng Tang which is effective for arthromyodynia management. METHODS: In this study, LC-MS identify the main component of YQCP. Ingredients of the 11 herbs were collected from Traditional Chinese Medicine Integrated Database (TCMID). Targets of these ingredients were collected from two source, TCMID and PharmMapper. Microarray of 20 early untreated RA patients and corresponding health control were download from NCBI Gene Expression Omnibus (GEO) database to defined the differential expressed genes. Gene ontology analysis and KEGG enrichment analysis were carried out for the YQCP. Protein-protein interactions (PPIs) networks were constructed to identify the hub targets. At last, molecular docking (MD) were conducted to further verified the the possibility of YQCP for RA therapy. RESULT: The study indicated that by acting on hub targets such as C3, EGFR, SRC and MMP9, YQCP may influence the mature of B cells and inhibit B cell-related IgG production, regulate oxidative stress and modulate activity of several enzymes including peroxidase and metallopeptidase to delay the occurrence and progress of RA and benefit the pre-RA or early RA patients. CONCLUSION: YQCP is a potential effective therapy for prophylactic treatment of RA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12906-021-03311-4.
format Online
Article
Text
id pubmed-8122573
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-81225732021-05-17 Network analysis indicating the pharmacological mechanism of Yunpi-Qufeng-Chushi-prescription in prophylactic treatment of rheumatoid arthritis Li, Lin Zhou, Donghai Liu, Qiuping Li, Dianming Wang, Qiao Shi, Xiaowei Wen, Chengping Huang, Lin BMC Complement Med Ther Research BACKGROUND: Rheumatoid arthritis (RA), is an autoimmune inflammatory disease with increasing global morbidity and high disability. Early treatment is an effective intervention to slow down joint deformation. However, as for early RA and pre-RA patients, it sometimes takes a long time to make a definite diagnosis and few guidelines have made suggestion for these suspected or early phrase individuals. Yunpi-Qufeng-Chushi-Prescription (YQCP) is an optimization of the traditional formula, Cangzhu Fangfeng Tang which is effective for arthromyodynia management. METHODS: In this study, LC-MS identify the main component of YQCP. Ingredients of the 11 herbs were collected from Traditional Chinese Medicine Integrated Database (TCMID). Targets of these ingredients were collected from two source, TCMID and PharmMapper. Microarray of 20 early untreated RA patients and corresponding health control were download from NCBI Gene Expression Omnibus (GEO) database to defined the differential expressed genes. Gene ontology analysis and KEGG enrichment analysis were carried out for the YQCP. Protein-protein interactions (PPIs) networks were constructed to identify the hub targets. At last, molecular docking (MD) were conducted to further verified the the possibility of YQCP for RA therapy. RESULT: The study indicated that by acting on hub targets such as C3, EGFR, SRC and MMP9, YQCP may influence the mature of B cells and inhibit B cell-related IgG production, regulate oxidative stress and modulate activity of several enzymes including peroxidase and metallopeptidase to delay the occurrence and progress of RA and benefit the pre-RA or early RA patients. CONCLUSION: YQCP is a potential effective therapy for prophylactic treatment of RA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12906-021-03311-4. BioMed Central 2021-05-15 /pmc/articles/PMC8122573/ /pubmed/33992108 http://dx.doi.org/10.1186/s12906-021-03311-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Li, Lin
Zhou, Donghai
Liu, Qiuping
Li, Dianming
Wang, Qiao
Shi, Xiaowei
Wen, Chengping
Huang, Lin
Network analysis indicating the pharmacological mechanism of Yunpi-Qufeng-Chushi-prescription in prophylactic treatment of rheumatoid arthritis
title Network analysis indicating the pharmacological mechanism of Yunpi-Qufeng-Chushi-prescription in prophylactic treatment of rheumatoid arthritis
title_full Network analysis indicating the pharmacological mechanism of Yunpi-Qufeng-Chushi-prescription in prophylactic treatment of rheumatoid arthritis
title_fullStr Network analysis indicating the pharmacological mechanism of Yunpi-Qufeng-Chushi-prescription in prophylactic treatment of rheumatoid arthritis
title_full_unstemmed Network analysis indicating the pharmacological mechanism of Yunpi-Qufeng-Chushi-prescription in prophylactic treatment of rheumatoid arthritis
title_short Network analysis indicating the pharmacological mechanism of Yunpi-Qufeng-Chushi-prescription in prophylactic treatment of rheumatoid arthritis
title_sort network analysis indicating the pharmacological mechanism of yunpi-qufeng-chushi-prescription in prophylactic treatment of rheumatoid arthritis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122573/
https://www.ncbi.nlm.nih.gov/pubmed/33992108
http://dx.doi.org/10.1186/s12906-021-03311-4
work_keys_str_mv AT lilin networkanalysisindicatingthepharmacologicalmechanismofyunpiqufengchushiprescriptioninprophylactictreatmentofrheumatoidarthritis
AT zhoudonghai networkanalysisindicatingthepharmacologicalmechanismofyunpiqufengchushiprescriptioninprophylactictreatmentofrheumatoidarthritis
AT liuqiuping networkanalysisindicatingthepharmacologicalmechanismofyunpiqufengchushiprescriptioninprophylactictreatmentofrheumatoidarthritis
AT lidianming networkanalysisindicatingthepharmacologicalmechanismofyunpiqufengchushiprescriptioninprophylactictreatmentofrheumatoidarthritis
AT wangqiao networkanalysisindicatingthepharmacologicalmechanismofyunpiqufengchushiprescriptioninprophylactictreatmentofrheumatoidarthritis
AT shixiaowei networkanalysisindicatingthepharmacologicalmechanismofyunpiqufengchushiprescriptioninprophylactictreatmentofrheumatoidarthritis
AT wenchengping networkanalysisindicatingthepharmacologicalmechanismofyunpiqufengchushiprescriptioninprophylactictreatmentofrheumatoidarthritis
AT huanglin networkanalysisindicatingthepharmacologicalmechanismofyunpiqufengchushiprescriptioninprophylactictreatmentofrheumatoidarthritis